Login
$FDMT
$11.29 -$0.94 (7.69%) Live

$FDMT SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition
10 Nov 2026 SCHEDULE 13G
20 Oct 2026 Form 4: Bizily Scott, Chief Legal Officer

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($21K)

07 Oct 2026 Form 4: Kirn David, Director

Sold 58,333 shares ($754K)

05 Oct 2026 144
28 Sep 2026 8-K: Other Events

On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular...

22 Sep 2026 Form 4: Bizily Scott, Chief Legal Officer

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($22.3K)

16 Sep 2026 Form 4: Kirn David, Director

Sold 58,333 shares ($811K)

14 Sep 2026 144
03 Sep 2026 Form 4: Bizily Scott, Chief Legal Officer

Received 584 shares by exercise or conversion ($3.79K) · Sold 584 shares ($8.18K)

21 Aug 2026 Form 4: Kirn David, Director

Received 50,000 shares by exercise or conversion ($207K) · Sold 69,076 shares ($1.09M)

19 Aug 2026 144
17 Aug 2026 Form 4: Bizily Scott, Chief Legal Officer

Received 1,635 shares by exercise or conversion ($6.77K) · Sold 1,635 shares ($19.6K) · Received 1,635 shares by exercise or conversion ($6.77K) · 1 more

17 Aug 2026 144
13 Aug 2026 144
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027

05 Aug 2026 Form 4: Kirn David, Director

Sold 26,842 shares ($275K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support